Etanercept Effective for Moderate to Severe Psoriasis

Zepe, Bill
June 2004
American Family Physician;6/1/2004, Vol. 69 Issue 11, p2675
Academic Journal
Presents a study that examined the use of etanercept, a synthetic protein that binds an inflammatory signal protein, in the treatment of psoriasis. Facts about psoriasis; Prevalence of psoriasis worldwide; Side effect of the drug.


Related Articles

  • Pediatric psoriasis. Gagnon, Louise // Dermatology Times;Apr2008, Vol. 29 Issue 4, p47 

    The article presents a new research which indicates that etanercept, a systematic agent, holds promise for treating moderate to severe psoriasis in the pediatric population in the U.S. According to the study, patients did not develop a tolerance to therapy. Extended follow-up of patients will...

  • Efficacy and Safety of Etanercept in Psoriasis/Psoriatic Arthritis. Romero-Maté, Alberto; García-Donoso, Carmen; Córdoba-Guijarro, Susana // American Journal of Clinical Dermatology;2007, Vol. 8 Issue 3, p143 

    The introduction in recent years of biologic medicines has greatly changed the treatment of psoriasis and psoriatic arthropathy (PsA). These drugs have been effective in the treatment of these chronic, physically weakening disorders, offering good efficacy and a safety profile that differs from...

  • Safety of Etanercept in Psoriasis: A Critical Review. Carazo, Jose L. Sánchez; Santos, Laura Mahiques; Martinez, Vicente Oliver // Drug Safety;2006, Vol. 29 Issue 8, p675 

    Conventional systemic treatments for patients with psoriasis are associated with multiple adverse effects that require continuous monitoring. The introduction of new biological agents such as etanercept, a fully human fusion protein, has permitted individualisation of patients’...

  • Etanercept Injection Site Reaction. Clelland, Susan; Hunek, Jeffrey R. // Dermatology Nursing;Oct2005, Vol. 17 Issue 5, p375 

    This article presents the case study of a 20-year-old female presented with a history of psoriasis and psoriatic arthritis since childhood. She started treatment with the drug called etanercept. There are certain side effects of this drug. As this drug is administered through injection,...

  • Psoriasis's changing face. Petrou, IIya // Dermatology Times;Jul2009, Vol. 30 Issue 7, p91 

    The article offers information related to psoriasis, including its history, current treatment and biologics. It mentions that psoriasis is well known in 1841 and its tropical treatment for localized psoriasis can include tar, topical corticosteroids, topical calcipotriene and topical tazarotene....

  • Etanercept.  // Reactions Weekly;9/16/2006, Issue 1119, p12 

    The article presents a case report involving a 30-year-old woman who developed psoriasis during treatment with the drug etanercept for rheumatoid arthritis. After two months of receiving etanercept along with prednisone, methotrexate and diclofenac, the patient presented with well-demarcated...

  • Treatment of psoriasis with etanercept: An experience from South Kuwait. Al-Abdulrazzaq, Adel; Zadeh, Valid Bagher; Al-Otaibi, Sultan; Tarrab, Sahar; Najem, Nabeel // Journal of Pakistan Association of Dermatologists;2012, Vol. 22 Issue 2, p136 

    Objective To observe the efficacy and safety profile of etanercept in patients with moderate to severe plaque psoriasis. Patients and methods In this retrospective study, 56 patients were treated with etanercept between May 2005 and May 2008. All patients were screened for tuberculosis. They...

  • NEWS FLASH.  // Good Health & Medicine;Mar2008, p13 

    The article reports that people with psoriasis can now access a subsidized medication that offers relief from symptoms. Remicade, or infliximab, is already available on the PBS.

  • Etanercept beats psoriasis: Biologic therapy increases quality of life for children, adolescents, as well as adults. Petrou, Ilya // Dermatology Times;May2009, Vol. 30 Issue 5, p50 

    The article discusses the therapeutic benefits of etanercept (Enbrel, Immunex) in improving the well-being of children and adolescents suffering from moderate-to-severe psoriasis. It outlines the study conducted by Doctor Amy S. Paller, professor and chairman of dermatology, at Northwestern...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics